Tobias A W Holderried
Overview
Explore the profile of Tobias A W Holderried including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neidhofer C, Klein N, Yuruktumen A, Hattenhauer T, Mispelbaum R, Bode C, et al.
Front Cell Infect Microbiol
. 2025 Feb;
15:1504262.
PMID: 39949721
Introduction: Bloodstream infections are a critical challenge worldwide due to the slow turnaround time of conventional microbiological tests for detecting bacteremia in septic patients. Noscendo GmbH (Duisburg, Germany) has developed...
2.
Zeyen T, Weller J, Schneider M, Potthoff A, Schaub C, Roever L, et al.
Neurooncol Adv
. 2025 Feb;
7(1):vdaf005.
PMID: 39902392
Background: Polychemotherapy based on high-dose methotrexate (HD-MTX) is the standard therapy for newly diagnosed younger patients (<65 years) with primary CNS lymphoma (PCNSL). In the modified Bonn protocol, consolidation therapy...
3.
Richardson T, Schutte D, Kobbe G, Baermann B, Holderried T, Schmitz F, et al.
Blood Adv
. 2025 Jan;
9(6):1370-1375.
PMID: 39746178
No abstract available.
4.
Mai E, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al.
J Clin Oncol
. 2024 Dec;
:JCO2402266.
PMID: 39652594
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of...
5.
Merz M, Dima D, Hashmi H, Ahmed N, Stolzel F, Holderried T, et al.
Blood Cancer J
. 2024 Dec;
14(1):214.
PMID: 39632797
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies...
6.
DeFilipp Z, Fox L, Holderried T, Mehra V, Michonneau D, Pashley A, et al.
Transplant Cell Ther
. 2024 Nov;
31(2):76.e1-76.e13.
PMID: 39536878
The objective of this meta-analysis (MA) was to evaluate the efficacy and safety of extracorporeal photopheresis (ECP) for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD). A systematic literature review...
7.
Richardson T, Kobbe G, Fenk R, Schroeder T, Crysandt M, Neuerburg C, et al.
Eur J Haematol
. 2024 Nov;
114(3):423-428.
PMID: 39535309
A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients relapse. Allogeneic hematopoietic cell transplantation (allo-SCT) is a...
8.
Holderried T, Stasik I, Schmitz M, Schmitz F, Meyer T, Stauss L, et al.
Front Digit Health
. 2024 Nov;
6:1414442.
PMID: 39498102
Background: The use of online information and communication is globally increasing in the healthcare sector. In addition to known benefits in other medical fields, possible specific potentials of eHealth lie...
9.
Penack O, Peczynski C, Boreland W, Lemaitre J, Reinhardt H, Afanasyeva K, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):114.
PMID: 39424959
No abstract available.
10.
Neuerburg C, Schmitz F, Schmitz M, Rehnelt S, Schumacher M, Parcina M, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1195.e1-1195.e13.
PMID: 39299503
Background: Prophylactic antibiotics are still controversial during allogeneic hematopoietic stem cell transplantation (allo-HSCT). In our transplant center, we suspended antibiotic prophylaxis during allo-HSCT in 2017. Objective: The main objective of...